Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

United Community Banks Inc (UCB)

United Community Banks Inc (UCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,624,264
  • Shares Outstanding, K 119,180
  • Annual Sales, $ 1,313 M
  • Annual Income, $ 187,540 K
  • 60-Month Beta 0.90
  • Price/Sales 2.65
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade UCB with:

Options Overview Details

View History
  • Implied Volatility 59.43% ( +11.50%)
  • Historical Volatility 34.63%
  • IV Percentile 57%
  • IV Rank 71.75%
  • IV High 63.96% on 08/08/24
  • IV Low 47.93% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 386
  • Open Int (30-Day) 332

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.58
  • Number of Estimates 5
  • High Estimate 0.61
  • Low Estimate 0.57
  • Prior Year 0.45
  • Growth Rate Est. (year over year) +28.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.96 +12.80%
on 08/05/24
31.96 -4.85%
on 07/26/24
+0.48 (+1.60%)
since 07/23/24
3-Month
24.04 +26.50%
on 06/17/24
31.96 -4.85%
on 07/26/24
+4.73 (+18.42%)
since 05/23/24
52-Week
21.63 +40.59%
on 11/01/23
31.96 -4.85%
on 07/26/24
+3.54 (+13.17%)
since 08/23/23

Most Recent Stories

More News
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine...

UCB : 30.41 (+4.18%)
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

FDA approval of RYSTIGGO® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis...

UCB : 30.41 (+4.18%)
UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

/PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain...

UCB : 30.41 (+4.18%)
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

UCB : 30.41 (+4.18%)
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA® in LGS provide significant reduction in the frequency of multiple seizure types...

UCB : 30.41 (+4.18%)
Iktos Announce Collaboration with UCB in AI for Retrosynthesis

Iktos, a company specialized in Artificial Intelligence for new drug design and UCB, a global biopharma company focusing on neurology and immunology, today announced a software licensing agreement related...

UCB : 30.41 (+4.18%)
Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB

Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson’s Disease. UCB0599...

UCB : 30.41 (+4.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

United Community Bank is a bank holding company. United conducts its operations through a community-focused operating model of separate community banks, which, as of December 31, 2016, operated at 139 locations throughout the Atlanta-Sandy Springs-Roswell, Georgia, and Gainesville, Georgia metropolitan...

See More

Key Turning Points

3rd Resistance Point 33.06
2nd Resistance Point 32.10
1st Resistance Point 31.26
Last Price 30.41
1st Support Level 29.46
2nd Support Level 28.50
3rd Support Level 27.65

See More

52-Week High 31.96
Last Price 30.41
Fibonacci 61.8% 28.01
Fibonacci 50% 26.79
Fibonacci 38.2% 25.58
52-Week Low 21.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar